Wong, Deysi Viviana T.; Ribeiro Filho, Helder Veras; Wanderley, Carlos Wagner Souza; Leite, Caio Abner Vitorino Gonçalves; Lima, Jonilson Berlink; Assef, Alexia Nathália Brígido; Cajado, Aurilene Gomes; Batista, Gabriela Loiola Ponte; González, Rafael Holanda; Silva, Karla Oliveira; Borges, Luis Philipi Carvalho; Alencar, Nylane Maria Nunes de; Wilke, Diego Veras; Cunha, Thiago Mattar 
; Figueira, Ana Carolina Migliorini; Cunha, Fernando de Queiroz ; Lima Júnior, Roberto César P.
Source: Cancer Chemotherapy and Pharmacology. Unidade: FMRP
Subjects: INFLAMAÇÃO, FÁRMACOS, RECEPTORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WONG, Deysi Viviana T. et al. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemotherapy and Pharmacology, v. 84, n. 2, p. 287-298, 2019Tradução . . Disponível em: https://doi.org/10.1007/s00280-019-03844-z. Acesso em: 25 jun. 2024.APA
Wong, D. V. T., Ribeiro Filho, H. V., Wanderley, C. W. S., Leite, C. A. V. G., Lima, J. B., Assef, A. N. B., et al. (2019). SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4. Cancer Chemotherapy and Pharmacology, 84( 2), 287-298. doi:10.1007/s00280-019-03844-zNLM
Wong DVT, Ribeiro Filho HV, Wanderley CWS, Leite CAVG, Lima JB, Assef ANB, Cajado AG, Batista GLP, González RH, Silva KO, Borges LPC, Alencar NMN de, Wilke DV, Cunha TM, Figueira ACM, Cunha F de Q, Lima Júnior RCP. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4 [Internet]. Cancer Chemotherapy and Pharmacology. 2019 ; 84( 2): 287-298.[citado 2024 jun. 25 ] Available from: https://doi.org/10.1007/s00280-019-03844-zVancouver
Wong DVT, Ribeiro Filho HV, Wanderley CWS, Leite CAVG, Lima JB, Assef ANB, Cajado AG, Batista GLP, González RH, Silva KO, Borges LPC, Alencar NMN de, Wilke DV, Cunha TM, Figueira ACM, Cunha F de Q, Lima Júnior RCP. SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4 [Internet]. Cancer Chemotherapy and Pharmacology. 2019 ; 84( 2): 287-298.[citado 2024 jun. 25 ] Available from: https://doi.org/10.1007/s00280-019-03844-z
